Click here to view our latest press releases, SEC filings, and information about company events, media, and analyst coverage. read more
Click here to learn more about our lead product candidate, MST-188, as well as our other technologies. read more
We have initiated a Phase 3 clinical study of MST-188 for the treatment of sickle cell disease. See our Clinical Trials page for more info. read more